Patent US4479794A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4479794A Expired / Lapsed US ⏱️ 0.0 years remaining

System for intravenous therapy

Assignee: Alza Corp
•
Filing: 1983-10-11
•
Granted: 1984-10-30
•
Expires: 2003-10-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A parenteral delivery system is disclosed for administering a beneficial agent to a recipient. The system comprises (a) a container of a medical fluid; (b) a primary tubing in communication with the container; (c) a parallel tubing connected to the primary tubing having a formulation chamber connected thereto, the formulation chamber housing a beneficial agent, or a device for delivering a beneficial agent; and (d) a common tubing connected to the primary tubing and the parallel tubing for administering the fluid and the agent to a recipient.

Inventors

  • 👤 John Urquhart
  • 👤 Felix Theeuwes

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 05:13
CPC Classifications
A; A61; A61M; A61M5/00; A61M5/14; A61M5/1407; A61M5/1409; A61M5/142; A61M5/145; A61M2005/14513

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 188 words
An administration set for use with a parenteral therapeutic system, the administration set comprising: (a) a primary tube for the flow of a medical fluid therethrough; (b) a parallel tube in fluid communication with the primary tube for the flow of medical fluid therethrough; and, (c) a drug formulation chamber connected to the parallel tube, the chamber comprising: (1) a wall surrounding a lumen; (2) an inlet in the wall that communicates with the parallel tube for admitting fluid into the chamber; (3) a fluid permeable film in the formulation chamber, said film a releasing means formed of a material that releases drug from said chamber in the presence of fluid that enters the chamber; (4) a drug in a pharmaceutically acceptable solid form in the formulation chamber and present in therapeutically effective amount for executing a prescribed thereapeutic beneficial program, said drug initially separated from the film, is contacted by fluid that enters the chamber, and is released from said chamber by the film and the fluid that flows therethrough; and, (5) an outlet in the wall for the flow of fluid containing drug from the chamber.
Claim 2
Dependent Claim 188 words
An administration set for use with a parenteral therapeutic system, the administration set comprising: (a) a primary tube for the flow of a medical fluid therethrough; (b) a parallel tube in fluid communication with the primary tube for the flow of medical fluid therethrough; and, (c) a drug formulation chamber connected to the parallel tube, the chamber comprising: (1) a wall surrounding a lumen; (2) an inlet in the wall that communicates with the parallel tube for admitting fluid into the chamber; (3) a fluid permeable film in the formulation chamber, said film a releasing means formed of a material that releases drug from said chamber in the presence of fluid that enters the chamber; (4) a drug in a pharmaceutically acceptable solid form in the formulation chamber and present in therapeutically effective amount for executing a prescribed thereapeutic beneficial program, said drug initially separated from the film, is contacted by fluid that enters the chamber, and is released from said chamber by the film and the fluid that flows therethrough; and, (5) an outlet in the wall for the flow of fluid containing drug from the chamber.
Claim 3
Dependent Claim 22 words
The administration set for use with the parenteral therapeutic system according to claim 1, wherein the drug in solid form is crystalline.
Claim 4
Dependent Claim 23 words
The administration set for use with the parenteral therapeutic system acording to claim 1, wherein the drug in solid form is a powder.
Claim 5
Dependent Claim 22 words
The administration set for use with the parenteral therapeutic system according to claim 1, wherein the drug in solid form is dried.
Claim 6
Dependent Claim 23 words
The administration set for use with the parenteral therapeutic system according to claim 1, wherein the drug in solid form is a particle.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-10-30 1988-04-30 1988-10-30 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-10-30 1992-04-30 1992-10-30 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-10-30 1996-04-30 1996-10-30 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag